Estrogen Receptors alpha and beta in Ovarian Cancer: Expression Level and Prognosis

The quantitative immunofluorescence assay of serous ovarian cancer tissue for the expression of estrogen receptors (ERα and ERβ) revealed a higher expression level of ERβ in comparison with ERα in all surgical tumor samples investigated. Significant differences in the expression level of the markers...

Full description

Saved in:
Bibliographic Details
Published in:Doklady. Biochemistry and biophysics 2018-09, Vol.482 (1), p.249-251
Main Authors: Bogush, T. A., Basharina, A. A., Bogush, E. A., Ryabinina, O. M., Tjulandina, A. S., Tjulandin, S. A.
Format: Article
Language:English
Subjects:
Biochemistry
Biological and Medical Physics
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Biomedical and Life Sciences
Biophysics
Chemotherapy
Disease-Free Survival
Estrogen Receptor alpha - metabolism
Estrogen Receptor beta - metabolism
Estrogen receptors
Female
Fluorescent Antibody Technique
Humans
Immunofluorescence
Life Sciences
Medical prognosis
Molecular Biology
Ovarian cancer
Ovarian carcinoma
Ovarian Neoplasms - diagnosis
Platinum
Prognosis
Transcriptome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The quantitative immunofluorescence assay of serous ovarian cancer tissue for the expression of estrogen receptors (ERα and ERβ) revealed a higher expression level of ERβ in comparison with ERα in all surgical tumor samples investigated. Significant differences in the expression level of the markers were detected “from tumor to tumor.” A high expression level of both ERα (≥ 25%) and ERβ (≥ 44%) in the tumor predicts a significantly longer progression-free survival time ( p < 0.01) in the patients after the first line of platinum and taxane-based adjuvant chemotherapy.
ISSN:1607-6729
1608-3091
DOI:10.1134/S1607672918050058